
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Brain Tumor Research Center [S. L. H., G. M., A. B., K. L., M. D. P., B. G. F.] and Neuro-Oncology Service [S. L. H., M. D. P.], Department of Neurological Surgery, and Departments of Laboratory Medicine [G. M., B. G. F.] and Pathology [A. B.], School of Medicine, University of California, San Francisco, California 94143
Glioblastoma multiforme (GM) is the most common and most malignant astrocytoma in adults. After surgery, radiation therapy extends patient survival; however, in vivo response to radiation therapy is variable. The purpose of this investigation was to determine whether the cytogenetic abnormalities of GM differ according to patient response to radiation therapy. Radiation response was defined by either progression [radiation-resistant (RR)] or resolution [radiation-sensitive (RS)] of tumor at the first postradiation radiographic imaging evaluation. Twenty RR and 10 RS frozen tissue specimens were subjected to cytogenetic analysis by comparative genomic hybridization. RS and RR specimens had different cytogenetic aberrations that mapped predominantly to chromosomes 7, 9, 10, 13, and 19. Relative gain of 7 occurred in 70% of the RR and 30% of the RS cases and was the most significant difference involving a single change between the two groups (P = 0.06). RR and RS specimens also differed in their patterns of simultaneous cytogenetic aberrations. A simultaneous gain of chromosomes 7 and 19 was found in 30% of the RR cases but was absent in the RS group. Concurrent loss of 9p2324 and 13q14 regions was absent in the RS cohort but occurred in 30% of the RR series. This latter cytogenetic pattern was also associated with older age. Amplifications were more common in the RR series, but the difference did not reach statistical significance. The data suggest that GM with different in vivo responses to radiation therapy also differ cytogenetically.
This article has been cited by other articles:
![]() |
M. Wrensch, J. K. Wiencke, J. Wiemels, R. Miike, J. Patoka, M. Moghadassi, A. McMillan, K. T. Kelsey, K. Aldape, K. R. Lamborn, et al. Serum IgE, Tumor Epidermal Growth Factor Receptor Expression, and Inherited Polymorphisms Associated with Glioma Survival. Cancer Res., April 15, 2006; 66(8): 4531 - 4541. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Pelloski, A. Mahajan, M. Maor, E. L. Chang, S. Woo, M. Gilbert, H. Colman, H. Yang, A. Ledoux, H. Blair, et al. YKL-40 Expression is Associated with Poorer Response to Radiation and Shorter Overall Survival in Glioblastoma Clin. Cancer Res., May 1, 2005; 11(9): 3326 - 3334. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Misra, M. Pellarin, J. Nigro, I. Smirnov, D. Moore, K. R. Lamborn, D. Pinkel, D. G. Albertson, and B. G. Feuerstein Array Comparative Genomic Hybridization Identifies Genetic Subgroups in Grade 4 Human Astrocytoma Clin. Cancer Res., April 15, 2005; 11(8): 2907 - 2918. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. C. Burton, K. R. Lamborn, B. G. Feuerstein, M. Prados, J. Scott, P. Forsyth, S. Passe, R. B. Jenkins, and K. D. Aldape Genetic Aberrations Defined by Comparative Genomic Hybridization Distinguish Long-Term from Typical Survivors of Glioblastoma Cancer Res., November 1, 2002; 62(21): 6205 - 6210. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Smith, I. Tachibana, S. M. Passe, B. K. Huntley, T. J. Borell, N. Iturria, J. R. O'Fallon, P. L. Schaefer, B. W. Scheithauer, C. D. James, et al. PTEN Mutation, EGFR Amplification, and Outcome in Patients With Anaplastic Astrocytoma and Glioblastoma Multiforme J Natl Cancer Inst, August 15, 2001; 93(16): 1246 - 1256. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hirose, K. Aldape, A. Bollen, C. D. James, D. Brat, K. Lamborn, M. Berger, and B. G. Feuerstein Chromosomal Abnormalities Subdivide Ependymal Tumors into Clinically Relevant Groups Am. J. Pathol., March 1, 2001; 158(3): 1137 - 1143. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. H. Joshi, G. E. Plautz, and R. K. Puri Interleukin-13 Receptor {{alpha}} Chain: A Novel Tumor-associated Transmembrane Protein in Primary Explants of Human Malignant Gliomas Cancer Res., March 1, 2000; 60(5): 1168 - 1172. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |